New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... - PR-inside.com (press release)

New Phase II study in gout patients shows Novartis ACZ885 prevented acute ... PR-inside.com (press release) Gout patients also have comorbidities making it more difficult for them to find an appropriate treatment," said Dr Naomi Schlesinger, Department of Medicine ... and more »

All About Gout: Arcalyst Meets Phase III Prophylaxis Endpoint - BioWorld Online

All About Gout: Arcalyst Meets Phase III Prophylaxis Endpoint BioWorld Online So Arcalyst essentially "provides a way for patients to take their gout medicine," he added. It's the production of IL-1 that stimulates the uric acid ... Regeneron's Gout Drug Prevents Painful Flares, Research FindsBusinessWeek ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 ...PR Newswire (press release) all 74 news articles »

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease - MarketWatch (press release)

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease MarketWatch (press release) ... a pro-inflammatory cytokine involved in diseases including Type 2 diabetes, cardiovascular disease, rheumatoid arthritis, gout and auto-inflammatory ... and more »

News > Gout Drug May Also Relieve Angina - Arthritis Today

News > Gout Drug May Also Relieve Angina Arthritis Today ... MD, professor of Cardiovascular Medicine at the University of Dundee, in Scotland. Allopurinol, sold under the brand Zyloprim, is used as a gout drug ...